Display options
Cite
Miller CP, Valliant-Saunders K, Blau CA. Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression. Transl Oncol. 2010;3(3):176-80doi: 10.1593/tlo.09304.
Miller, C. P., Valliant-Saunders, K., & Blau, C. A. (2010). Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression. Translational oncology, 3(3), 176-80. https://doi.org/10.1593/tlo.09304
Miller, Chris P, et al. "Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression." Translational oncology vol. 3,3 (2010): 176-80. doi: https://doi.org/10.1593/tlo.09304
Miller CP, Valliant-Saunders K, Blau CA. Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression. Transl Oncol. 2010 Jun 01;3(3):176-80. doi: 10.1593/tlo.09304. PMID: 20563259; PMCID: PMC2887647.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2010 Jun 01;3(3):176-80. doi: 10.1593/tlo.09304.

Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression.

Translational oncology

Chris P Miller, Karine Valliant-Saunders, Carl Anthony Blau

Affiliations

  1. Department of Medicine/Hematology and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.

PMID: 20563259 PMCID: PMC2887647 DOI: 10.1593/tlo.09304

Abstract

Adverse effects of erythropoietin (EPO) on tumor progression and survival were observed in recent phase 3 oncology trials. However, mechanisms remain poorly understood. We tested the effects of exogenous EPO on murine B16F10 melanoma growth in a subcutaneous tumor transplant model, and for the first time, in a model of spontaneous tumor formation within autochthonous epithelial tissues using murine mammary tumor virus promoter polyoma virus middle T antigen (MMTV-PyMT) transgenic mice. EPO receptor (EPOR) messenger RNA (mRNA) was detectable in both B16F10 tumors and mammary tumors from MMTV-PyMT mice but was 0.12 +/- 0.02% and 1.3 +/- 0.91% of the EPOR mRNA level in murine erythroid HCD-57 cells, respectively. B16F10 tumor growth rates in mice treated for 3 weeks with 30 microg/kg per week of darbepoetin alpha, 0.41 inverse days (range, 0.05-0.69 inverse days; n = 16), were similar to tumor growth rates observed in mice treated with PBS, 0.42 inverse days (range, 0.10-0.69 inverse days; n = 17). In contrast, darbepoetin alpha raised hematocrit levels to 0.593 (maximum, 0.729) compared with 0.448 (maximum, 0.532) in PBS-treated mice (P = .0004). In MMTV-PyMT mice, the weights of tumor-bearing mammary glands in mice treated for 6 weeks with 30 microg/kg per week of darbepoetin alpha, 3.37 g (range, 1.94-5.81 g; n = 27), did not significantly differ from the weights in PBS-treated mice, 3.76 g (range, 2.30-6.33 g; n = 26). In contrast, darbepoetin alpha raised hematocrit levels to 0.441 (maximum, 0.606) compared with 0.405 (maximum, 0.492) in PBS-treated mice (P = .05). Thus, effects of exogenous EPO on tumor growth were not recapitulated in these murine tumor models.

References

  1. Lancet. 2009 May 2;373(9674):1532-42 - PubMed
  2. Cancer Res. 1997 Aug 15;57(16):3520-5 - PubMed
  3. PLoS One. 2007 Jun 20;2(6):e549 - PubMed
  4. Lancet. 2003 Oct 18;362(9392):1255-60 - PubMed
  5. Breast Cancer Res. 2000;2(3):211-6 - PubMed
  6. Acta Otolaryngol. 2006 May;126(5):545-7 - PubMed
  7. J Clin Oncol. 2007 Mar 20;25(9):1027-32 - PubMed
  8. J Clin Oncol. 2005 Sep 1;23(25):5960-72 - PubMed
  9. Mol Cell Biol. 1992 Mar;12(3):954-61 - PubMed
  10. Clin Cancer Res. 2008 Aug 1;14(15):4685-90 - PubMed
  11. Carcinogenesis. 2003 Jun;24(6):1021-9 - PubMed
  12. Neoplasia. 2008 Sep;10(9):932-9 - PubMed
  13. J Clin Oncol. 2008 Mar 1;26(7):1040-50 - PubMed
  14. Br J Cancer. 2001 Mar 23;84(6):836-43 - PubMed
  15. Transgenic Res. 2007 Apr;16(2):193-201 - PubMed
  16. Am J Pathol. 2003 Nov;163(5):2113-26 - PubMed
  17. Blood. 1991 Mar 15;77(6):1228-33 - PubMed
  18. Proc Soc Exp Biol Med. 1962 Jul;110:436-40 - PubMed
  19. Zentralbl Pathol. 1992 Sep;138(4):266-70 - PubMed
  20. Cancer. 2007 Aug 1;110(3):477-88 - PubMed
  21. Genomics. 2001 Jun 15;74(3):253-61 - PubMed
  22. JAMA. 2008 Feb 27;299(8):914-24 - PubMed
  23. Expert Rev Mol Med. 2008 Dec 01;10:e36 - PubMed

Publication Types

Grant support